Markets
BSE See NSE See 38,040.57
15.12 (0.04%)

Vaishali Pharma launches Vitamin C supplements to boost immunity

Apurva Joshi
/ Categories: DSIJ Mindshare
Rate this article:
3.4
Vaishali Pharma launches Vitamin C supplements to boost immunity

Vaishali Pharma Limited has launched Vipravita C (Vitamin C supplements) for domestic as well as international market to boost immunity against various prevailing diseases. These supplements are available in different variants like Vitamin C chewable tablets, Vitamin C effervescent tablets and Vitamin C with zinc combo.

Vitamin C is beneficial in many contexts like boosting antioxidant levels, lowering blood pressure, protecting against gout attacks, improving iron absorption, reducing heart disease as well as dementia risk, other than boosting immunity.

Boosting one's immunity system has become the need of the hour, especially during this COVID-19 pandemic situation. The company has a strong portfolio of immunity products and plans to double the product range in the coming years. In April, to fight against the pandemic, the company had launched personal care and hygiene products, such as sanitisers, personal protective equipment (PPE), face shields and face masks.

It has also been seeking product registrations in various countries along with certain approvals, which are currently under the pipeline. Currently, it has over 80 formulation brands marketed in multiple countries and also, built a robust pipeline of around 250 dossiers (with around 120 approvals).

Earlier in June, the company had forayed into the dermatology therapy segment by launching two anti-fungal brands. It already had a strong base in export markets and with this launch, it will now be able to strengthen its position even in the domestic markets.

On Tuesday, the stock of Vaishali Pharma opened 2.2 per cent higher at Rs 51.45 from its previous close of Rs 50.35 on NSE. During the day, it slipped by 4.3 per cent making an intraday low of Rs 48.20. Later, it got closed at Rs 49.

Previous Article Cipla gets USFDA nod for Icatibant Injectable
Next Article Sensex tanks by more than 600 points; IndusInd Bank declines by over 5 per cent

Please login or register to post comments.

DSIJ MINDSHARE

12345Last